IBRX
ImmunityBioBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Q1 preliminary revenue growth, expanding ANKTIVA geographic reach, and a fully enrolled QUILT-2.005 study support a real commercial-plus-regulatory path if the upcoming 10-Q validates the preliminary figures and 2026 regulatory milestones stay on track [#8-K-2026-04-09].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -1.8.
What can break
Formal Q1 2026 results could disappoint versus the April 9 preliminary figures.
Momentum
90
Value
41
Sentiment
46
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.50 · Bull $11.00 · Bear $4.50
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $13.00
Why
Momentum90 · Δ7d -1.8
Value41 · Δ7d +0.0
Sentiment46 · Δ7d +3.1
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
90
26% active weight
Current posture
7d trendSoftening
Δ7d
-1.8
Δ21d
+15.2
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
46
34% active weight
Current posture
7d trendImproving
Δ7d
+3.1
Δ21d
+9.7
Why this grade
Composite grade B. Momentum 90.2 / Value 41.1 / Sentiment 46.3
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$8.45B
Beta
-0.02
Shares Out
1.05B
P/E (TTM) · Derived
-21.1
P/S (TTM)
24.82
P/FCF (TTM) · Derived
-25.89
Rev YoY
+167.6%
EPS YoY
+305.4%
Gross Margin
+87.9%
Op Margin
-315.8%
Net Debt
$601.85M
Current Ratio
6.67
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology